Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) shares rose 2.1% during mid-day trading on Friday . The company traded as high as $38.57 and last traded at $37.78, with a volume of 849,379 shares trading hands. The stock had previously closed at $36.99.

ZLTQ has been the topic of a number of research reports. Maxim Group boosted their target price on shares of Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a “buy” rating in a research report on Tuesday. TheStreet upgraded shares of Zeltiq Aesthetics from a “hold” rating to a “buy” rating in a research report on Wednesday, April 20th. Leerink Swann restated a “buy” rating on shares of Zeltiq Aesthetics in a research note on Thursday, June 30th. Stifel Nicolaus restated a “buy” rating and set a $38.00 price target on shares of Zeltiq Aesthetics in a research note on Friday, May 13th. Finally, Zacks Investment Research upgraded shares of Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a research note on Saturday, July 23rd. Three analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.33.

The stock has a 50 day moving average of $31.49 and a 200-day moving average of $27.26. The stock has a market capitalization of $1.49 billion and a PE ratio of 56.90.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its earnings results on Monday, August 8th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.05) by $0.07. During the same period in the previous year, the company earned $0.03 EPS. The firm earned $89.50 million during the quarter, compared to the consensus estimate of $79.68 million. Zeltiq Aesthetics’s quarterly revenue was up 38.9% on a year-over-year basis. Equities research analysts expect that Zeltiq Aesthetics Inc. will post ($0.07) earnings per share for the current year.

In other news, insider Keith J. Sullivan sold 8,000 shares of the firm’s stock in a transaction dated Monday, July 11th. The stock was sold at an average price of $30.02, for a total transaction of $240,160.00. Following the completion of the sale, the insider now directly owns 77,922 shares in the company, valued at $2,339,218.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Bradley Hauser sold 3,000 shares of the firm’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $30.02, for a total value of $90,060.00. Following the sale, the vice president now owns 47,184 shares of the company’s stock, valued at $1,416,463.68. The disclosure for this sale can be found here.

Other hedge funds have made changes to their positions in the company. New York State Common Retirement Fund increased its stake in shares of Zeltiq Aesthetics by 4.3% in the fourth quarter. New York State Common Retirement Fund now owns 41,532 shares of the company’s stock valued at $1,185,000 after buying an additional 1,700 shares in the last quarter. Trexquant Investment LP purchased a new position in Zeltiq Aesthetics during the fourth quarter worth approximately $1,640,000. California State Teachers Retirement System increased its position in Zeltiq Aesthetics by 1.7% in the fourth quarter. California State Teachers Retirement System now owns 59,726 shares of the company’s stock worth $1,704,000 after buying an additional 984 shares during the period. State of Tennessee Treasury Department purchased a new position in Zeltiq Aesthetics during the fourth quarter worth approximately $2,853,000. Finally, Wells Fargo & Company MN increased its position in Zeltiq Aesthetics by 765.2% in the fourth quarter. Wells Fargo & Company MN now owns 404,376 shares of the company’s stock worth $11,537,000 after buying an additional 357,636 shares during the period.

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.